| Study Period | 2019 - 2030 |
| 乐鱼体育官网 Size (2025) | USD 0.82 Billion |
| 乐鱼体育官网 Size (2030) | USD 1.22 Billion |
| CAGR (2025 - 2030) | 8.23 % |
| Fastest Growing 乐鱼体育官网 | Asia-Pacific |
| Largest 乐鱼体育官网 | North America |
| 乐鱼体育官网 Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Huntington's Disease Treatment 乐鱼体育官网 Analysis
The Huntington's Disease Treatment 乐鱼体育官网 size is estimated at USD 0.82 billion in 2025, and is expected to reach USD 1.22 billion by 2030, at a CAGR of 8.23% during the forecast period (2025-2030).
Huntington鈥檚 disease is an inherited disorder that results in the breakdown of nerve cells and impairs brain function. Factors such as the growing burden of Huntington鈥檚 disease and the surge in disease awareness levels are the key factors expected to drive the 乐鱼体育官网 growth during the forecast period. In addition, the growing efforts from manufacturers to develop effective treatment modalities for the condition are further expected to accelerate 乐鱼体育官网 growth.
The significant burden of Huntington鈥檚 disease around the globe is anticipated to accelerate demand for effective treatment regimens to manage the increased disease burden. For instance, according to a study published in an article published by the Journal of Huntington's Disease in June 2022, the burden of Huntington鈥檚 disease is on the rise in Canada, and there is a significant gap in the effective treatment of the disease.
The significant disease burden and unmet treatment needs are expected to create lucrative growth opportunities for 乐鱼体育官网 participants. This is expected to drive the development of advanced treatment options for the disease and stimulate 乐鱼体育官网 growth during the forecast period.
In addition, the increased efforts to develop promising treatments for all stages of Huntington鈥檚 disease and positive topline results from those investigational treatments are expected to support 乐鱼体育官网 growth during the forecast period. For instance, according to an article published by Pharmaceuticals in October 2023, several effective disease-modifying and symptomatic therapies paved their way through clinical trials to manage Huntington鈥檚 disease. In addition, these therapies promoted neurogenesis while improving brain function. Significant research and development efforts will likely foster industry expansion during the forecast period.
Moreover, the presence of a high volume of investigational candidates in the late phase of clinical trials and their anticipated launch during the forecast period is further likely to propel industry uptake. For instance, according to June 2024 data from the Clinical Trial Gov, there were around 69 studies in Phase II of the clinical trial, followed by 25 studies in Phase III. Thus, much higher volumes of investigational candidates and their projected launches during the forecast period are further expected to expedite industry expansion.
Also, several strategic initiatives 乐鱼体育官网 participants undertake to strengthen their business avenues are further expected to spur industry expansion during the forecast period. For instance, in April 2024, Skyhawk Therapeutics and Ipsen formed a collaboration agreement to develop small molecules that modulate RNA for rare neurological diseases, including Huntington鈥檚 disease.
In addition, positive topline results from investigational studies are further expected to propel 乐鱼体育官网 growth during the forecast period. For instance, in December 2023, uniQure NV published the results from the Phase I/II clinical trials of AMT-130 to manage Huntington鈥檚 disease. The overall results were very promising and showed disease stability in patients. Thus, such ongoing developments will likely accelerate 乐鱼体育官网 growth during the forecast period.
Thus, the surge in the burden of Huntington鈥檚 disease, increased demand for effective disease treatment, and growing research activities are expected to accelerate industry expansion during the forecast period. However, the high cost of developing effective treatment is expected to hamper the 乐鱼体育官网's growth during the forecast period.
Huntington's Disease Treatment 乐鱼体育官网 Trends
The Symptomatic Treatment Segment is Expected to Hold a Major 乐鱼体育官网 Share During the Forecast Period
Symptomatic treatment of Huntington鈥檚 disease majorly focuses on motor impairment and chorea. Chorea remains the most prominent clinical feature of Huntington's disease, for which most therapeutic studies have been conducted. Relatively high availability and usage rates of symptom management therapeutics are expected to account for a significant share during the forecast period.
The rising need for multiple treatments and the intervention of a multispecialty care team for symptomatic management resulting in additional expenses may contribute to the development of the segment during the forecast period.
Key factors such as rising awareness campaigns and increasing product developments by various 乐鱼体育官网 players are expected to contribute to the growth of the segment. For instance, in May 2023, Neurocrine Biosciences Inc. reported complete findings from the Phase 3 KINECT-HD study investigating Valbenazine for treating Huntington's disease (HD) chorea. According to the company, Valbenazine showed a statistically significant improvement over the placebo in the Total Maximal Chorea (TMC) score.
In September 2022, Teva Pharmaceutical launched the Honestly HD website to help people better understand what to expect from Huntington's disease (HD) chorea, one of HD's most apparent and curable symptoms, and how to communicate to their doctor about maintaining independence.
Also, the surge in emphasis on symptomatic treatment of disease is further expected to accelerate segment expansion during the forecast period. For instance, according to an article published by Neurological Research and Practice in November 2023, treatment approaches such as pharmacotherapy and behavioral treatments should be individually adapted to manage several signs and symptoms of Huntington鈥檚 disease, including myoclonus, dystonia, and chorea. Thus, such increased emphasis on symptomatic treatment of disease is likely to augment segment expansion during the forecast period.
Therefore, key players' continuous R&D activities and awareness programs are expected to create lucrative opportunities for the segment during the forecast period.
Understand The Key Trends Shaping This 乐鱼体育官网
Download PDF
North America is Expected to Hold a Significant 乐鱼体育官网 Share During the Forecast Period
North America is expected to hold a significant 乐鱼体育官网 share during the forecast period due to the rising incidence of Huntington's disease, the presence of key players, and growing R&D funding by the government and private organizations. According to the April 2024 updated data of McGill University, Huntington鈥檚 disease has emerged as a significant disease in Canada, and it affects around 1 in 7,000 people in Canada. As Huntington's condition becomes more prevalent in this region, demand for efficient treatments is anticipated to rise, driving the growth of the target 乐鱼体育官网 throughout the forecast period.
Companies ' increasing product development and R&D activities are expected to fuel the 乐鱼体育官网's growth during the forecast period. For instance, in June 2024, PTC Therapeutics Inc. published the Phase II interim results from the PIVOT-HD study of PTC518 in Huntington's disease (HD) patients. The results showed a significant decrease in mutant huntingtin (mHTT) protein in the blood. Thus, such increased product development activities and R&D activities by the 乐鱼体育官网 participants are likely to foster the development of new therapeutics, which is expected to boost 乐鱼体育官网 growth during the forecast period.
Moreover, the growing funding activities for Huntington鈥檚 disease research in the United States are further anticipated to accelerate 乐鱼体育官网 growth. For instance, according to 2024 updated data from the National Institute of Health, the estimated funding for Huntington鈥檚 disease research ramped from 49 million in 2024 to 50 million in 2025. Thus, the growing research funding for Huntington鈥檚 disease will likely accelerate the development of novel therapeutics, which, in turn, is projected to boost 乐鱼体育官网 growth during the forecast period.
Also, the growing regulatory approvals of novel therapeutics are further expected to propel the commercialization of innovative treatment options, further boosting 乐鱼体育官网 growth during the forecast period. For instance, in August 2023, the US Food and Drug Administration approved Neurocrine Biosciences Inc.鈥檚 INGREZZA (valbenazine) capsules for the management of chorea associated with Huntington's disease. Such approvals are anticipated to propel regional 乐鱼体育官网 growth during the forecast period.
As a result, the rising prevalence of the target disease, increased R&D, and supportive regulatory authorities are anticipated to contribute to the 乐鱼体育官网 expansion in this region during the forecast period.
Get Analysis on Important Geographic 乐鱼体育官网s
Download PDF
Huntington's Disease Treatment Industry Overview
The Huntington's disease treatment 乐鱼体育官网 is competitive with several large, small, and medium-sized players. Some of the companies dominating the 乐鱼体育官网 are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ceregene Inc., Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd, Ionis Pharmaceuticals, Neurocrine Biosciences Inc., Prilenia Therapeutics, Azevan Pharmaceuticals, and Lundbeck.
Huntington's Disease Treatment 乐鱼体育官网 Leaders
-
Pfizer, Inc.
-
Alnylam Pharmaceuticals Inc.
-
Teva Pharmaceutical Industries Ltd.
-
Neurocrine Biosciences, Inc.
-
Ionis Pharmaceuticals
- *Disclaimer: Major Players sorted in no particular order
Need More Details on 乐鱼体育官网 Players and Competiters?
Download PDF
Huntington's Disease Treatment 乐鱼体育官网 News
- May 2024: The US Food and Drug Administration approved AUSTEDO XR of Teva Pharmaceuticals as a one-pill, once-daily treatment option for the treatment of Huntington鈥檚 disease (HD) chorea control and tolerable tardive dyskinesia.
- October 2023: Sage Therapeutics Inc.鈥檚 SAGE-718 received an orphan Drug Designation (ODD) from the US Food and Drug Administration to manage Huntington鈥檚 disease (HD).
Huntington's Disease Treatment Industry Segmentation
As per the scope of this report, Huntington's disease treatment covers various treatment modalities that are commercially available. It is a genetic disorder that mostly occurs between 30 and 50 years, leading to the degeneration of nerve cells in the brain.
The Huntington's disease treatment 乐鱼体育官网 is segmented by type and end user. By type, the 乐鱼体育官网 is segmented as symptomatic treatment and disease-modifying therapies. By end user, the 乐鱼体育官网 is segmented as hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the 乐鱼体育官网 is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
| By Type | Symptomatic Treatment | ||
| Disease-modifying Therapies | |||
| By Distribution Channel | Hospital Pharmacies | ||
| Retail Pharmacies | |||
| Online Pharmacies | |||
| By Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Huntington's Disease Treatment 乐鱼体育官网 Research FAQs
How big is the Huntington's Disease Treatment 乐鱼体育官网?
The Huntington's Disease Treatment 乐鱼体育官网 size is expected to reach USD 0.82 billion in 2025 and grow at a CAGR of 8.23% to reach USD 1.22 billion by 2030.
What is the current Huntington's Disease Treatment 乐鱼体育官网 size?
In 2025, the Huntington's Disease Treatment 乐鱼体育官网 size is expected to reach USD 0.82 billion.
Who are the key players in Huntington's Disease Treatment 乐鱼体育官网?
Pfizer, Inc., Alnylam Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals are the major companies operating in the Huntington's Disease Treatment 乐鱼体育官网.
Which is the fastest growing region in Huntington's Disease Treatment 乐鱼体育官网?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Huntington's Disease Treatment 乐鱼体育官网?
In 2025, the North America accounts for the largest 乐鱼体育官网 share in Huntington's Disease Treatment 乐鱼体育官网.
What years does this Huntington's Disease Treatment 乐鱼体育官网 cover, and what was the 乐鱼体育官网 size in 2024?
In 2024, the Huntington's Disease Treatment 乐鱼体育官网 size was estimated at USD 0.75 billion. The report covers the Huntington's Disease Treatment 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Huntington's Disease Treatment 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Huntington's Disease Treatment Industry Report
Statistics for the 2025 Huntington's Disease Treatment 乐鱼体育官网 share, size and revenue growth rate, created by Mordor Intelligence鈩� Industry Reports. Huntington's Disease Treatment analysis includes a 乐鱼体育官网 forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
